SCHEMBL2585953

SCHEMBL2585953

O=C(Nc1ccc(N2CCN(Cc3ccccc3)CC2)cc1)c1ccccc1-c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.70
MAPK1 P28482 2/20 0.70
TSHR P16473 1/20 0.70
SMN1; SMN2 Q16637 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
USP2 O75604 1/20 0.61
NPY2R P49146 2/20 0.59
LMNA P02545 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
ALDH1A1 P00352 2/20 0.56
HTT P42858 1/20 0.56
ATM Q13315 1/20 0.56
CHRNB2 P17787 1/20 0.56
CHRNB4 P30926 1/20 0.56
CHRNA3 P32297 1/20 0.56
CHRNA4 P43681 1/20 0.56
KMT2A Q03164 2/20 0.55
HSD17B10 Q99714 1/20 0.55
MAP4K4 O95819 1/20 0.53
NTRK1 P04629 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2588205 0.90 HIF1A (0.64) MAPTMAPK1TSHRSMN1; SMN2L3MBTL1
SCHEMBL13841347 0.84 MLNR (0.56) MAPTMAPK1TSHRNPSR1ALDH1A1
SCHEMBL2586188 0.82 HDAC3 (0.54) MAPTMAPK1TSHRSMN1; SMN2NPSR1
SCHEMBL6698830 0.82 HIF1A (0.56) MAPTMAPK1TSHRSMN1; SMN2L3MBTL1
SCHEMBL2582475 0.81 CHRNB2 (0.61) MAPTMAPK1TSHRSMN1; SMN2L3MBTL1
SCHEMBL9742938 0.79 MEN1 (0.70) MAPTMAPK1TSHRSMN1; SMN2L3MBTL1
SCHEMBL2586334 0.79 NAMPT (0.63) MAPTMAPK1TSHRSMN1; SMN2L3MBTL1
SCHEMBL13219520 0.79 RAB9A (0.77) MAPTMAPK1TSHRSMN1; SMN2L3MBTL1
SCHEMBL6698014 0.78 CA1 (0.52) MAPTSMN1; SMN2NPY2RLMNAALDH1A1
SCHEMBL12157819 0.78 NPY2R (0.79) MAPTMAPK1TSHRNPY2RCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354402-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-15 US disclosed
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2011-11-03 US disclosed
EP-1317431-B1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS JANSSEN PHARMACEUTICA NV (BE) 2010-10-20 EP disclosed
US-7528154-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICAL N.V. (BE) 2009-05-05 US disclosed
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2008-05-29 US disclosed
US-7253157-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 US disclosed
EP-1806341-A2 (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 EP disclosed
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2007-04-12 US disclosed
US-7169796-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-30 US disclosed
EP-1379515-B1 LIPID LOWERING BIPHENYLCARBOXAMIDES JANSSEN PHARMACEUTICA NV (BE) 2006-12-27 EP disclosed
US-20060241113-A1 Polyarylcarboxamides useful as lipid lowering agents MEERPOEL LIEVEN 2006-10-26 US disclosed
US-20050159402-A1 Polyarylcarboxamides useful as lipid lowering agents MEERPOEL LIEVEN (BE) 2005-07-21 US disclosed
US-6878724-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN-PHARMACEUTICA N.V. (BE) 2005-04-12 US disclosed
US-20040014971-A1 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159402-A1 Polyarylcarboxamides useful as lipid lowering agents LIPC, PNLIP, APOB MAPT 4545/4885MAPK1 4372/4885TSHR 2871/4885
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB MAPT 4545/4885MAPK1 4372/4885TSHR 2871/4885
US-20060241113-A1 Polyarylcarboxamides useful as lipid lowering agents LIPC, PNLIP, APOB MAPT 4545/4885MAPK1 4372/4885TSHR 2871/4885
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB MAPT 4545/4885MAPK1 4372/4885TSHR 2871/4885
US-20040014971-A1 Polyarylcarboxamides useful as lipid lowering agents SREBF1, LIPC, CPT1A MAPT 4632/4885MAPK1 2533/4885TSHR 3353/4885
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB MAPT 4545/4885MAPK1 4372/4885TSHR 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.